Recently,Global Peptide and Oligonucleotide (TIDES) Field Sees Series of Advances.Zealand Pharma's treatment for overweight or obesity and type 2 diabetesLong-acting amylin analog pEtrelintide (ZP8396) has completed the recruitment of the first subject in the Phase 2b clinical trial.Gan&Lee Pharmaceuticals IsletSu YuGlucagon-like peptide-1 (GLP-1) Receptor AgonistFixed-dose combination drug approved for clinical use in China, the drug'sThe dosing frequency is on a weekly basis.Rona Therapeutics for the treatment of hypertensionSmall interfering RNA (siRNA) drug RN1871 approved for clinical trials in China.

Welcome readers to long press/scanDepict withScan the QR code below to apply for access to the complete table."April 2025, Issue 4: Progress in TIDES Therapy"。

▲Long press to scan the QR code above and apply for the "Summary of TIDES Therapy Advances, April 2025, Issue 4"

Petrelintide: First Patient Enrolled in Phase 2b Clinical Trial

Zealand Pharma Announces First Patient Dosed in Phase 2b Trial of Petrelintide for Overweight or Obesity and Type 2 DiabetesPetrelintide (ZP8396) is a long-acting amylin analog suitable for once-weekly subcutaneous injection., with chemical and physical stability at neutral pH. Amylin is produced in the pancreatic β-cells and secreted together with insulin in response to ingested nutrients.In March 2025, Zealand Pharma and Roche reached a global collaboration and licensing agreement to jointly develop petrelintide as a cornerstone therapy for weight management.

Current clinical or preclinical data suggest that petrelintide has the potential to achieveGLP-1 receptor agonists achieve comparable weight loss but with better tolerability, offering patients an improved medication experience and enhancing the quality of weight loss by preserving muscle mass. Previously announced...Phase 1b Clinical Trial ResultsDisplay,After 16 weeks of high-dose petrelintide treatment, patients experienced an average weight loss of 8.6%, compared to only 1.7% in the placebo group.

GZR102 Injection: Approved for Clinical Trials in China

The official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that Gan&Lee Pharmaceuticals' Class 1 new drug GZR102 has received implied permission for clinical trials in China, intended for the development of treatment for Type 2 diabetes. According to Gan&Lee Pharmaceuticals' announcement,GZR102 Injection is a fixed-ratio combination formulation of its self-developed basal insulin GZR4 injection and GLP-1 receptor agonist bofanaglutide (GZR18) injection, with a dosing frequency measured in weeks.This is the first time that the product has been approved for clinical use in China.

Currently, the global development of GZR4 alone and Boefan Glucagon is in the Phase 3 clinical research stage.Compared with single-component, GZR102 is expected to reduce glycated hemoglobin (HbA1c) more effectively, has better weight control advantages compared with basal insulin, and is expected to reduce the risk of hypoglycemia.At the same time, currently available fixed-ratio combination drugs of basal insulin/GLP-1 receptor agonists on the market are daily formulations, requiring patients to inject daily. GZR102 injection is expected to reduce injection frequency while achieving good safety and efficacy, further improving patient medication adherence and enhancing the quality of life for patients with type 2 diabetes.

RN1871: Approved for Clinical Trials in China

Rona Therapeutics Announces IND Approval by China NMPA for RN1871, a Self-developed siRNA Drug Targeting Angiotensinogen (AGT)This therapy precisely inhibits the production of the core precursor protein of the renin-angiotensin-aldosterone system (RAAS) by silencing the mRNA expression of AGT in the liver.The RAAS system is a key pathway in blood pressure regulation, and its overactivation is closely related to the progression of hypertension. Preclinical studies have shown that RN1871 can effectively reduce blood pressure over the long term, offering the potential for a better treatment option for more than 1.5 billion hypertension patients worldwide.

Due to limited space,This article only provides a brief introduction to some significant advancements.。Readers are welcome to long press/scan the following QR code to apply for the "Summary of TIDES Therapy Advances - April 2025, Issue 4" containing the complete table.

▲Press and hold to scan the QR code above, apply for the "Summary of TIDES Therapy Advances - April 2025, Issue 4"

[1] Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. Retrieved April 21, 2025, from https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c

[2] Gan&Lee Pharmaceuticals Announcement on Receiving the "Drug Clinical Trial Approval Notice". Retrieved April 21, 2025, from http://www.cninfo.com.cn/new/disclosure/detail?stockCode=603087&announcementId=1223190962&orgId=9900026770&announcementTime=2025-04-22

[3] Rona Therapeutics Announces RN1871 – siRNA Drug Targeting Angiotensinogen (AGT) Receives NMPA Clinical Trial Implied Permission. Retrieved April 21, 2025, from https://mp.weixin.qq.com/s/KlQvkqoQ3p5gD6nu7sGYmg

[4] Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity. Retrieved April 21，2025, from   https://www.globenewswire.com/news-release/2024/12/10/2994577/0/en/Zealand-Pharma-announces-first-participant-enrolled-in-Phase-2b-ZUPREME-1-trial-of-petrelintide-in-people-with-overweight-or-obesity.html